Ocular Therapeutix Inc - Asset Resilience Ratio
Ocular Therapeutix Inc (OCUL) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Ocular Therapeutix Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2017)
This chart shows how Ocular Therapeutix Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Ocular Therapeutix Inc.
Liquid Assets Composition Over Time
This chart breaks down Ocular Therapeutix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Ocular Therapeutix Inc for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Ocular Therapeutix Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Ocular Therapeutix Inc Industry Peers by Asset Resilience Ratio
Compare Ocular Therapeutix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Ocular Therapeutix Inc (2012–2017)
The table below shows the annual Asset Resilience Ratio data for Ocular Therapeutix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $55.43 Million | -- |
| 2016-12-31 | 46.98% | $35.21 Million | $74.94 Million | -20.36pp |
| 2015-12-31 | 67.34% | $74.28 Million | $110.31 Million | +19.46pp |
| 2014-12-31 | 47.88% | $37.44 Million | $78.19 Million | +47.56pp |
| 2013-12-31 | 0.31% | $60.00K | $19.15 Million | +0.08pp |
| 2012-12-31 | 0.24% | $60.00K | $25.29 Million | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more